Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VanEck Biotech ETF (NQ:BBH)

183.08 -4.41 (-2.35%)
Official Closing Price Updated: 4:15 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about VanEck Biotech ETF

PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
Via Stocktwits
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
Time For Gilead Sciences-Heavy ETFs? ↗
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
News headline image
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of... 
Via Benzinga
News headline image
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
News headline image
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
News headline image
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
News headline image
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗
 
Via Benzinga
News headline image
US Judge Weighs Nationwide Ban On Abortion Pills ↗
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
News headline image
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗
 
Via Benzinga
News headline image
3 Best Funds for Aggressive Investors ↗
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
News headline image
Progenity Is Unlikely to Live Up to Its IPO Hype ↗
Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech? 
Via InvestorPlace
News headline image
How Are Biotech ETFs Reacting To These Q3 Earnings Releases? ↗
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
News headline image
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone ↗
After the formidable run, NVAX stock has come under significant pressure, but between its pipeline and its Covid vaccine, it is a dip buy. 
Via InvestorPlace
News headline image
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money ↗
With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in. 
Via InvestorPlace
News headline image
Take A Look At The Top-Performing Biotech ETFs YTD ↗
The biotechnology sector has been grabbing the headlines on the new coronavirus vaccine and drug-related updates. The space has also kept its promise of generating returns, with the Nasdaq... 
Via Talk Markets
News headline image
Biotech ETFs To Benefit From Latest Booster Update ↗
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from... 
Via Talk Markets
News headline image
ETF Investing Areas to Consider for August ↗
There is no doubt that the second-quarter 2021 earnings season is going strong. 
Via Talk Markets
News headline image
Moderna ETFs To Rise On Positive COVID-19 Vaccine Updates ↗
The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to... 
Via Talk Markets
News headline image
5 Top ETFs With Exposure To Biogen ↗
Here is a look at five ETFs with large exposure to Biogen shares. 
Via Talk Markets
News headline image
5 Top ETFs With Exposure To Biogen ↗
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
News headline image
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines ↗
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from... 
Via Talk Markets
Topics Intellectual Property
News headline image
Moderna Stock Moves After Q1 Print: Technical Levels For The COVID-19 Vaccine Play ↗
Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.